ERCC1 Expression

CI-VAR-00001037Explore in graph →CIViC 329

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Bladder Carcinoma3
ERCC1 Expression	(prognostic)	Prognostic	B	Supports Better Outcome	2	accepted	EID810 ERCC1 expression as evaluated by IHC in 432 patients was associated with better disease-free survival (HR 0.70, p = 0.028) and cancer specific survival (HR 0.70, p = 0.032) on multivariable analysis. PMID 26162296 · Klatte et al., 2015 · Open in CIViC	civic
ERCC1 Expression	Cisplatin	Predictive	B	Does Not Support Sensitivity Response	4	accepted	EID809 Immunhistochemistry of ERCC1 expression in 432 patients revealed no correlation to response to cisplatin based chemotherapy. In-vitro studies also did not show any effects. PMID 26162296 · Klatte et al., 2015 · Open in CIViC	civic
ERCC1 Expression

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Pleural Malignant Mesothelioma1
ERCC1 Expression	(prognostic)	Prognostic	B	Supports Poor Outcome	4	submitted	EID9234 The paper evaluated tissue samples from 73 patients (male and female) for IHC staining of ERCC1 and RRM1. They found that dual expression was associated with later stage MPM and poorer overall surviva… (full text at CIViC) PMID 32842027 · Zito Marino et al., 2021 · Open in CIViC	civic